179 related articles for article (PubMed ID: 31721140)
1. Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database.
Fakhri B; Fiala MA; Shah N; Vij R; Wildes TM
Cancer; 2020 Feb; 126(4):808-813. PubMed ID: 31721140
[TBL] [Abstract][Full Text] [Related]
2. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
Bishnoi R; Xie Z; Shah C; Bian J; Murthy HS; Wingard JR; Farhadfar N
Cancer Med; 2021 Jan; 10(1):70-78. PubMed ID: 33169938
[TBL] [Abstract][Full Text] [Related]
3. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
Mian HS; Fiala MA; Sanchez L; Vij R; Wildes TM
Ann Hematol; 2021 May; 100(5):1261-1266. PubMed ID: 33475778
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-World Database.
Nakao S; Uchida M; Satoki A; Okamoto K; Uesawa Y; Shimizu T
Oncology; 2022; 100(1):60-64. PubMed ID: 34673654
[TBL] [Abstract][Full Text] [Related]
5. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.
Chari A; Hajje D
BMC Cancer; 2014 Dec; 14():915. PubMed ID: 25471129
[TBL] [Abstract][Full Text] [Related]
6. Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma.
Chen JH; Lenihan DJ; Phillips SE; Harrell SL; Cornell RF
Cardiooncology; 2017; 3():4. PubMed ID: 32154000
[TBL] [Abstract][Full Text] [Related]
7. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Comorbid Medical Conditions in the National Cancer Database and the SEER-Medicare Database.
Lin CC; Virgo KS; Robbins AS; Jemal A; Ward EM
Ann Surg Oncol; 2016 Dec; 23(13):4139-4148. PubMed ID: 27535406
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
10. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
[TBL] [Abstract][Full Text] [Related]
11. Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).
Milano AF
J Insur Med; 2018; 47(4):203-211. PubMed ID: 30668210
[TBL] [Abstract][Full Text] [Related]
12. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
Siegel D; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K; Lonial S
Haematologica; 2013 Nov; 98(11):1753-61. PubMed ID: 23935022
[TBL] [Abstract][Full Text] [Related]
13. Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer.
Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
Int J Chron Obstruct Pulmon Dis; 2019; 14():893-903. PubMed ID: 31118599
[No Abstract] [Full Text] [Related]
14. Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database.
Wang K; Sheets NC; Basak R; Chen RC
Cancer; 2016 Oct; 122(19):3069-74. PubMed ID: 27352280
[TBL] [Abstract][Full Text] [Related]
15. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.
Waxman AJ; Clasen S; Hwang WT; Garfall A; Vogl DT; Carver J; O'Quinn R; Cohen AD; Stadtmauer EA; Ky B; Weiss BM
JAMA Oncol; 2018 Mar; 4(3):e174519. PubMed ID: 29285538
[TBL] [Abstract][Full Text] [Related]
17. Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data.
Goto D; Khairnar R; Yared JA; Yong C; Romanus D; Onukwugha E; Slejko JF
Cancer Med; 2020 Jan; 9(2):626-639. PubMed ID: 31801177
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans.
Ramsey SD; Scoggins JF; Blough DK; McDermott CL; Reyes CM
J Manag Care Pharm; 2009 Oct; 15(8):659-68. PubMed ID: 19803555
[TBL] [Abstract][Full Text] [Related]
19. Heart Failure Among Patients with Multiple Myeloma Treated with Carfilzomib-Based Versus Non-Carfilzomib-Based Regimens in the United States by Race.
Li S; Suehs BT; Fu A; Sangaré L; Kim C; Gastanaga VM; Liu J; Yan H; Xu Y; Mikhael J
Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):616-625. PubMed ID: 37258396
[TBL] [Abstract][Full Text] [Related]
20. Management of Carfilzomib-Associated Cardiac Adverse Events.
Mikhael J
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
